Dihexa for Lupus (SLE) Brain Fog & Neuropsychiatric Lupus (NPSLE): Anti-NMDA Antibodies, Anifrolumab Saphnelo, CAR-T (Erlangen), Deucravacitinib POETYK, BDNF, HGF/c-Met & the 2026 UK Review

Around 69,000-100,000 UK adults live with systemic lupus erythematosus (SLE), with the CPRD analysis (Yen, Singh & Singh, 2024) showing UK point prevalence rising from 21.4 per 100,000 in 1990 to 107.14 per 100,000 by 2020 (overall incidence 5.47 cases per 100,000 person-years). Women are affected approximately nine times more often than men, with onset peaking in the reproductive years; British South Asian and Black African / Caribbean women carry materially higher prevalence and disease severity. The Hanly meta-analysis pooled prevalence of measurable cognitive impairment in SLE is 38% (95% CI 33-43%); studies vary from 20-80% by case definition; up to 80% of SLE patients describe subjective brain fog. 2024-2026 has been the most consequential window in lupus medicine in a generation. In 2021, Mougiakakos, Mackensen, Schett and colleagues at the University of Erlangen-Nuremberg published in the New England Journal of Medicine the first case of CD19-targeted autologous chimeric antigen receptor (CAR) T-cell therapy in a 20-year-old woman with refractory SLE; she entered complete drug-free remission. The 2022 Nature Medicine paper expanded the cohort, and at EULAR 2024 the Erlangen group reported 11 of 12 SLE / lupus nephritis patients in drug-free remission at mean 458-day follow-up. The September 2025 Journal of Rheumatology preliminary quality-of-life and health-economic analysis of 8 patients followed >2 years confirmed the durability signal. In September 2024 the EU CHMP recommended approval of the subcutaneous self-administration prefilled-pen formulation of anifrolumab (Saphnelo, AstraZeneca) based on the TULIP-SC trial, with Q4 2024 launch across EU markets; the UK NICE position remains the terminated TA793 appraisal. In November 2025, Bristol Myers Squibb presented two late-breaking abstracts at ACR Convergence demonstrating Sotyktu (deucravacitinib) efficacy in SLE, with the PAISLEY-SLE four-year safety and efficacy integrated analysis supporting the now-enrolling POETYK SLE-1 and POETYK SLE-2 Phase 3 programme (~980 patients, 60 weeks). Biogen's litifilimab (BIIB059) anti-BDCA2 plasmacytoid dendritic cell monoclonal is in three Phase 3 trials (TOPAZ-1 SLE, TOPAZ-2 SLE, AMETHYST CLE). Meanwhile, the Diamond / Volpe DNRAb (anti-NMDA receptor NR2A/NR2B) paradigm has consolidated as the leading mechanistic model of antibody-mediated cognitive damage in NPSLE - with the awkward pharmacological implication that a synaptogenic peptide augmenting NMDA-dependent plasticity could amplify rather than relieve the damage. Against this backdrop, does Dihexa have anything to offer the UK's ~100,000 lupus patients - and is there a real theoretical risk that more HGF/c-Met-driven synaptic plasticity could worsen anti-NMDAR cognitive damage? This rigorous 2026 UK review covers what is actually known, what is speculation, and where the evidence is genuinely absent. Readers may also want to read the closely related Dihexa for Fibromyalgia & Fibro Fog review (22-25% lupus comorbidity), the Dihexa for ME/CFS review (substantial post-infectious overlap), the Dihexa for Long COVID Brain Fog review (immune-mediated brain-fog parallels), the Dihexa for Chemo Brain review (cyclophosphamide overlap), the Dihexa for Multiple Sclerosis review (autoimmune CNS demyelination parallels), the Dihexa for Depression & Mood review (NPSLE mood comorbidity), and the Dihexa for Anxiety & Stress review (NPSLE anxiety comorbidity).

Lupus (SLE) in the UK in 2026: Scale, Demographics & Why Brain Fog Matters

Systemic lupus erythematosus (SLE) is the prototype multi-system autoimmune disease and one of the most challenging chronic conditions in adult medicine. The 2024 CPRD analysis by Yen, Singh and Singh using the UK Clinical Practice Research Datalink reported point prevalence increasing approximately five-fold over three decades: 21.4 per 100,000 in 1990 to 107.14 per 100,000 by 2020, with overall incidence of 5.47 cases per 100,000 person-years. On 2020 population denominators that translates to approximately 69,000-100,000 UK adults living with diagnosed SLE, with the higher end reflecting the relatively younger CPRD-registered population. LUPUS UK uses the often-quoted figure of 50,000-69,000 UK adults; the true number is almost certainly higher when undiagnosed mild and incomplete-criteria disease are included.

The condition shows a striking female predominance - approximately 9:1 female:male ratio in adult-onset SLE - with onset peaking in the reproductive years (typically 15-45). UK ethnic disparities are pronounced: British African / Caribbean and South Asian women carry higher prevalence, earlier onset, more severe renal involvement (lupus nephritis), and worse long-term outcomes than the White British population. The CPRD analysis quantified increased standardised mortality ratio of approximately 1.4-1.8 over the period despite treatment advances. Mean diagnostic delay in the UK is consistently measured in years - the 2022 European 4,150-patient diagnostic-delay analysis reported a median delay of around 7 years from first symptom to diagnosis.

The diagnostic framework most widely used in 2026 is the 2019 EULAR/ACR classification criteria - a weighted 10-point system with a positive antinuclear antibody (ANA) of ≥1:80 by HEp-2 indirect immunofluorescence as the obligatory entry criterion, then domain points for fever, leucopenia, thrombocytopenia, autoimmune haemolysis, neuropsychiatric features (delirium, psychosis, seizure - the only NP domains in the criteria), mucocutaneous, serosal, musculoskeletal, renal, and immunological (anti-dsDNA, anti-Smith, anti-cardiolipin, lupus anticoagulant, hypocomplementaemia, direct Coombs test). The 2018 BSR guideline by Caroline Gordon and colleagues remains the UK reference, with the BSR 2024 scope expansion to children, young people and adults published in Rheumatology Advances in Practice.

Cognitive dysfunction and brain fog are extraordinarily common. Across the published literature the Hanly pooled-prevalence meta-analysis estimated 38% (95% CI 33-43%) meet criteria for measurable cognitive impairment on neuropsychological testing; individual study figures range from 20% to 80% depending on the case definition and battery used; and patient-reported subjective brain fog reaches ~80% in survey series. Creyos and the HSS lupus group have published widely on the executive-function and processing-speed pattern characteristic of SLE cognitive dysfunction.

NPSLE: The 1999 ACR 19 Syndromes Case Definition

Neuropsychiatric SLE (NPSLE) is the umbrella term for nervous-system involvement in lupus. The standard framework remains the 1999 ACR NPSLE case definition, which split nervous-system involvement into 19 syndromes - 12 central, 7 peripheral:

Central (12): aseptic meningitis; cerebrovascular disease (stroke, TIA, sinus venous thrombosis); demyelinating syndrome; headache (including lupus headache and benign intracranial hypertension); movement disorder (chorea); myelopathy; seizure disorder; acute confusional state (delirium); anxiety disorder; cognitive dysfunction; mood disorder; psychosis.

Peripheral (7): Guillain-Barre syndrome (acute inflammatory demyelinating polyradiculoneuropathy); autonomic disorder; mononeuropathy (single / multiplex); myasthenia gravis; cranial neuropathy; plexopathy; polyneuropathy.

Approximately 80-90% of SLE patients will experience at least one neuropsychiatric manifestation across the course of their disease, although the proportion attributable directly to lupus pathology (so-called primary NPSLE) versus secondary causes (steroid-induced psychosis, infection, metabolic derangement, drug interactions, depression / anxiety as reactive comorbidity, fibromyalgia / pain-mediated brain fog) is hotly debated. The SLICC attribution algorithm and the Bortoluzzi Italian algorithm are the most widely used clinical tools to attribute a given event to primary versus secondary NPSLE. Primary NPSLE in turn divides into focal NPSLE (cerebrovascular disease, often driven by antiphospholipid antibodies / secondary APS) and diffuse NPSLE (cognitive dysfunction, mood disorder, psychosis, acute confusional state).

The Modern Mechanistic Picture: Type I IFN, BAFF, Anti-NMDAR DNRAbs, BBB & HGF

Type I Interferon Signature

The single most important pathophysiological insight of the last twenty years in lupus is the dominance of the type I interferon (IFN-alpha, IFN-beta) signature in the peripheral blood transcriptome of approximately 60-80% of SLE patients. Plasmacytoid dendritic cells (pDCs) producing type I IFN in response to immune complexes containing nucleic acids form the core of the autoamplification loop. This insight underpins three classes of approved or late-stage SLE therapeutics: anifrolumab (Saphnelo) - a monoclonal antibody blocking the type I interferon receptor subunit 1 (IFNAR1) - approved by the FDA in July 2021 and by the EMA in February 2022 on the back of TULIP-1 and TULIP-2 Phase 3, with the September 2024 CHMP / Q4 2024 EU approval of the subcutaneous self-administration prefilled pen based on TULIP-SC; litifilimab (BIIB059) - an anti-BDCA2 monoclonal targeting pDCs themselves - in Phase 3 TOPAZ-1 SLE, TOPAZ-2 SLE and AMETHYST CLE; and deucravacitinib (Sotyktu) - an oral allosteric TYK2 inhibitor blocking downstream type I IFN, IL-12 and IL-23 signalling - with the November 2025 ACR PAISLEY-SLE 4-year data and the now-enrolling POETYK SLE-1 and POETYK SLE-2 Phase 3 programme.

BAFF / BLyS & the B-Cell Hyperactivity Axis

The B-cell activating factor of the TNF family (BAFF, also called BLyS) drives autoreactive B-cell survival and class-switching. Belimumab (Benlysta, GSK) is a fully human IgG1 monoclonal antibody blocking soluble BAFF and was the first targeted SLE biologic to gain regulatory approval (FDA 2011, EMA 2011, NICE TA397 June 2016 for autoantibody-positive SLE refractory to standard therapy; NICE TA752 in 2021 for the subcutaneous formulation; FDA approval for lupus nephritis in 2020 on the back of BLISS-LN). Belimumab is one of the most widely prescribed targeted SLE therapeutics in the UK.

The SLE Autoantibody Landscape

SLE is defined immunologically by the breadth and titre of autoantibodies. The clinically most relevant include: antinuclear antibody (ANA) - the screening test, positive in >95% of SLE; anti-double-stranded DNA (anti-dsDNA) - the most disease-specific marker, correlated with disease activity and renal flare; anti-Smith (anti-Sm) - the most specific marker for SLE (~99% specificity, ~30% sensitivity); anti-Ro/SSA (Ro52, Ro60) and anti-La/SSB - associated with Sjogren's overlap, photosensitive cutaneous lupus, and crucially neonatal lupus with congenital heart block in offspring of pregnant women; anti-U1RNP - associated with mixed connective tissue disease (MCTD); ribosomal-P - the Bonfa 1987 NEJM paper established the association with lupus psychosis and depression; antiphospholipid antibodies (aPL) - lupus anticoagulant, anti-cardiolipin (IgG, IgM), anti-beta-2-glycoprotein I (IgG, IgM, IgA) - present in 30-40% of SLE patients and defining the secondary antiphospholipid syndrome (APS) with thrombosis and pregnancy morbidity, including a substantial fraction of focal NPSLE cerebrovascular events.

The Anti-NMDA Receptor (DNRAb / Anti-NR2A/B) Paradigm

The most rigorously characterised antibody-mediated cognitive-impairment mechanism in any autoimmune disease was established by Betty Diamond, Bruce Volpe, Lorraine DeGiorgio and colleagues at the Feinstein Institute. The 2001 Nature Medicine paper showed that a subset of anti-dsDNA antibodies cross-react with a pentapeptide sequence (D-W-E-Y-S) in the extracellular domain of the NR2A and NR2B subunits of the NMDA receptor. These cross-reactive antibodies - termed DNRAbs (DNA- and NR2 receptor-reactive antibodies) - are present in approximately one-third to one-half of SLE patient sera and in a similar fraction of CSF samples in NPSLE. The Faust 2010 PNAS paper demonstrated in mice that breach of the blood-brain barrier - by lipopolysaccharide endotoxin or by adrenaline - allows DNRAbs to enter the brain and bind hippocampal CA1 pyramidal neurons and lateral amygdala neurons, producing region-specific cognitive and behavioural impairment. Memantine, the non-competitive NMDA-receptor antagonist used clinically in moderate-to-severe Alzheimer's, rescued the cognitive damage. CSF intrathecal synthesis of anti-NR2 has been documented in patients with diffuse psychiatric / neuropsychological NPSLE. This is the single most important mechanistic finding in the field for any synaptic-plasticity-modulating intervention - including, particularly, a synaptogenic peptide.

Blood-Brain Barrier & Cerebral Endothelial Damage

The Watson 1983 PNAS paper on lupus brain-reactive antibodies remains the foundational document for the BBB-permeability story. Stock and colleagues (2015 J Immunology) showed TLR4-mediated endotoxin disruption of BBB integrity allows autoantibody penetration. HGF/c-Met signalling is one of the most important protective regulators of cerebral endothelial cell function, brain pericyte survival, and BBB integrity (Wright & Harding 2015). The biological tension is direct: HGF/c-Met augmentation could protect the BBB (preventing autoantibody entry), or could augment NMDA-dependent synaptic plasticity (amplifying autoantibody damage once the antibodies are inside).

Microglial Neuroinflammation

Microglial activation is documented in NPSLE on TSPO-PET imaging (11C-PK11195, 11C-PBR28) and post-mortem neuropathology - mirroring the pattern documented in ME/CFS (Nakatomi 2014), fibromyalgia (Albrecht 2019), and Long COVID. The 2024 S100A8/A9 and MMP-9 cognitive-impairment biomarker paper linked elevated peripheral DAMPs / matrix-metalloproteinase activity to documented cognitive dysfunction in SLE.

BDNF in Lupus: Conflicting Data

The BDNF literature in SLE is conflicting. Petri and colleagues (2021 Clinical Rheumatology) cohort of 111 SLE patients reported decreased serum BDNF versus controls, inversely associated with hypertension and SLICC Damage Index scores - but importantly found no association between BDNF and cognitive dysfunction or NPSLE specifically. Other case-control series (Ikenouchi-Sugita 2010; Eilat) have reported either elevated or unchanged BDNF in SLE - the field has not settled on a directional signal. The Eilat / Caster 2013 case-control of serum and lymphocytic neurotrophin profiles reported elevated BDNF and NGF in SLE patients. This conflict probably reflects heterogeneity in disease activity state, treatment regimen and BDNF assay - rather than a clear biological story. The implication: there is no clean BDNF-deficit case to motivate a BDNF-augmenting peptide in lupus, the way there is in (for example) the Alzheimer's case.

HGF/c-Met in Lupus: The Paradoxical Elevation

Unlike the consistent decreased serum HGF signal that Russo and colleagues documented in OCD (2013), depression (2010), anxiety (2010), bipolar disorder (2010) and autism (2014), HGF appears to be elevated in active SLE. Yamamoto, Funahashi, Kobayashi and colleagues (1996) reported elevated serum HGF in active SLE that tracked with disease activity. Niwa, Mizuno, Matsumoto and colleagues (1999, Nephrology Dialysis Transplantation) reported elevated urinary HGF in lupus nephritis, which they interpreted as a compensatory renal-protective response. The dominant 2020s interpretation is that HGF/c-Met is upregulated in active SLE as part of a renal-protective and BBB-protective compensatory response - mirroring its protective role in cerebral ischaemia and stroke recovery (see our post-stroke recovery review). The implication for Dihexa is doubled-edged: if endogenous HGF is already up-regulated in active SLE, the marginal benefit of further pharmacological augmentation is unclear; if endogenous HGF up-regulation is protective, then sustaining or augmenting it may be reasonable; but if HGF up-regulation also contributes to B-cell/T-cell expansion driving the autoimmune flare, augmentation could worsen disease.

The 2026 UK Treatment Landscape: BSR Guideline, Hydroxychloroquine, Biologics & NICE TAs

UK SLE management is anchored by the 2018 BSR systemic lupus erythematosus guideline (Gordon et al.) with the BSR 2024 scope expansion published in Rheumatology Advances in Practice. The 2019 update of the EULAR recommendations for the management of SLE is the parallel European reference. The treatment paradigm in 2026 is built around five pillars:

1. Hydroxychloroquine - The Cornerstone

Hydroxychloroquine (Plaquenil) is recommended for virtually every SLE patient at 200-400mg daily (5mg/kg lean body weight ceiling per the Royal College of Ophthalmologists), unless contraindicated. It reduces flare rate, organ damage accrual, cardiovascular events and overall mortality. The most important safety concern is retinal toxicity; the Royal College of Ophthalmologists guidelines recommend annual screening from year 5 of therapy onward with OCT and visual field testing.

2. Conventional Synthetic DMARDs

Methotrexate (typically weekly oral or subcutaneous) is used for arthritic and cutaneous manifestations. Azathioprine (with mandatory TPMT and NUDT15 testing) is widely used for moderate disease and as a steroid-sparing agent. Mycophenolate mofetil (CellCept) or mycophenolate sodium (Myfortic) is the workhorse for lupus nephritis induction (typically 2-3g/day) and maintenance, often after a low-dose Euro-Lupus pulse cyclophosphamide induction regimen. Cyclophosphamide is reserved for severe organ-threatening disease (severe lupus nephritis class III/IV, NPSLE, alveolar haemorrhage) under specialist supervision.

3. Biologics & Targeted Therapies

Belimumab (Benlysta, GSK): NICE TA397 (June 2016) recommends belimumab IV; NICE TA752 (2021) recommends belimumab subcutaneous - both for active autoantibody-positive SLE despite standard therapy. FDA approval for paediatric (children ≥5 years) and lupus nephritis followed BLISS-LN.

Anifrolumab (Saphnelo, AstraZeneca): FDA-approved July 2021 (TULIP-1 / TULIP-2 Phase 3); EMA-approved February 2022. NICE TA793 was terminated because AstraZeneca did not provide an evidence submission - meaning Saphnelo is not NICE-recommended in England and Wales as of May 2026. The September 2024 CHMP positive recommendation and Q4 2024 EU approval of the subcutaneous self-administration prefilled-pen formulation based on TULIP-SC has not yet changed the UK NICE position. The 2026 update on the US regulatory review of SC anifrolumab indicates further FDA engagement.

Voclosporin (Lupkynis, Otsuka / Aurinia): NICE TA882 (April 2023) recommends voclosporin with mycophenolate mofetil for active class III, IV or V lupus nephritis, based on the AURORA-1 and AURORA-2 trials.

Rituximab (MabThera): a CD20-depleting anti-B-cell monoclonal antibody, widely used off-label for refractory SLE under NHS England rituximab access protocol for autoimmune disease, despite the EXPLORER and LUNAR trials having missed primary endpoints. The biological rationale was overtaken by the success of more targeted approaches (belimumab, anifrolumab, CAR-T).

4. The 2025-2026 Late-Stage Pipeline

Deucravacitinib (Sotyktu, Bristol Myers Squibb): oral selective allosteric TYK2 inhibitor already approved for plaque psoriasis. November 2025 BMS late-breaking ACR Convergence presented PAISLEY-SLE 4-year safety and efficacy data; POETYK SLE-1 and POETYK SLE-2 Phase 3 trials (NCT05617677 and NCT05620407) are enrolling - approximately 490 participants each, 60 weeks, deucravacitinib 12mg once daily vs placebo on background standard of care. Readouts expected 2026-2027.

Litifilimab (BIIB059, Biogen): humanised IgG1 anti-BDCA2 monoclonal antibody targeting plasmacytoid dendritic cells. LILAC Phase 2 in cutaneous lupus published in NEJM; PAISLE Phase 2 SLE positive. Biogen announced first patient dosed in Phase 3 SLE TOPAZ-1; TOPAZ-2 SLE and AMETHYST CLE also enrolling.

Iberdomide (Bristol Myers Squibb): cereblon-modulator E3 ubiquitin ligase modulator with Phase 2 SLE data. Ianalumab (VAY736, Novartis): anti-BAFF-receptor monoclonal in Phase 3 SIRIUS-SLE. Telitacicept (RemeGen): BLyS / APRIL dual inhibitor, approved in China, Phase 3 globally.

5. The CD19 CAR-T Cell Therapy Revolution

The single most consequential development in autoimmune medicine of the last twenty years. Mougiakakos, Mackensen, Schett and colleagues at the University of Erlangen-Nuremberg first reported in the New England Journal of Medicine (2021) a 20-year-old woman with severe refractory SLE who entered complete drug-free remission within weeks of a single autologous CD19 CAR-T infusion. The 2022 Nature Medicine paper expanded the cohort to 5 patients. At EULAR 2024 the Erlangen group reported 11 of 12 SLE / lupus nephritis patients in drug-free remission at mean 458-day follow-up; the September 2025 Journal of Rheumatology preliminary quality-of-life and health-economic analysis of 8 patients followed >2 years confirmed durability. The mechanistic insight is profound: deep B-cell depletion to undetectable levels in tissue (not just peripheral blood) followed by a naive B-cell repopulation appears to reset the autoimmune compartment.

Multiple commercial CAR-T programmes are now in pivotal trials globally: Kyverna KYV-101 (KYSA-1 / KYSA-3 lupus nephritis Phase 1/2); Cabaletta Bio CABA-201 RESET-SLE Phase 1/2; Cartesian Therapeutics Descartes-08 BCMA mRNA CAR-T; Bristol Myers Squibb bbT369 CD19 / CD20 dual; AstraZeneca C-CAR168 (RoseliCar) CD19 / BCMA dual; multiple other Chinese, US and European programmes. CAR-T for SLE is not currently available on the NHS outside of clinical trial; UK trial sites are listed on NIHR Be Part of Research.

NPSLE-Specific Management & Cognitive Dysfunction

NPSLE management is divided into the focal / inflammatory presentations (cerebrovascular disease, seizure, myelitis, demyelinating syndrome) which are managed with standard immunosuppression (high-dose corticosteroids, cyclophosphamide, mycophenolate, rituximab) plus disease-specific therapy (anticoagulation for aPL-positive thrombosis, anti-epileptics for seizure), and the diffuse / psychiatric / cognitive presentations (cognitive dysfunction, mood disorder, psychosis, acute confusional state) which are managed symptomatically with concurrent immunosuppression.

Cognitive dysfunction in SLE has no approved therapy in the UK or anywhere else. Empirical strategies include: optimising disease control (lower SLEDAI typically associated with better cognition); minimising glucocorticoid exposure (steroids themselves impair cognition); aggressive vascular-risk-factor management (hypertension, diabetes, dyslipidaemia, smoking, antiphospholipid antibody-driven thrombotic risk); anticoagulation in aPL-positive patients; cognitive rehabilitation (the same techniques used in stroke and post-COVID brain fog); treatment of depression / anxiety / sleep disturbance / pain (which all worsen cognition); and the 2020s LUPUS Brain transcranial alternating current stimulation (tACS) trial (NCT04141046).

An interesting recent development is the EG-501 NPSLE cognitive impairment Phase 2 study (NCT07281105) - one of the first direct attempts at a disease-specific pharmacological treatment of NPSLE cognitive dysfunction. As of May 2026 EG-501 represents an early-stage signal; no Phase 3 data exist.

The Diamond / Volpe DNRAb paradigm has not yet translated into a clinically approved NMDA-receptor-antagonist intervention for NPSLE cognitive impairment, despite the strong preclinical case for memantine. Multiple small trials of memantine in NPSLE cognitive dysfunction have produced mixed signals; no Phase 3 trial has been mounted.

Where Could Dihexa Theoretically Fit in Lupus Biology?

The honest summary: the biology is unusually complicated. The case is more direction-of-effect uncertain than for any other condition we have reviewed. NPSLE is the one condition where a synaptogenic, NMDA-augmenting peptide could plausibly amplify the very pathology (DNRAb-mediated NMDA-receptor activation in CA1 hippocampus and amygdala) that drives the cognitive damage. The protective BBB story partially counterbalances. There is no clean BDNF deficit to motivate augmentation. And HGF is already up-regulated in active disease.

Risks & Theoretical Concerns Specific to Lupus

Beyond the generic risks in the Dihexa side-effects review, lupus-specific concerns include: anti-NMDAR amplification (the central directionality concern - augmenting NMDA-dependent plasticity in a brain exposed to NMDA-receptor-activating autoantibodies); B-cell / T-cell proliferation (c-Met activation has been documented in lymphocyte expansion); renal involvement (any agent that could affect glomerular biology in a patient at risk of lupus nephritis flare warrants caution; HGF has known renal effects); thrombosis risk in aPL-positive patients (the secondary APS subset of SLE; angiogenic peptides theoretically affect coagulation cascade); pregnancy (SLE often presents and flares in reproductive-age women; teratogenicity of Dihexa is unstudied; pregnancy is a strict contraindication); polypharmacy interactions (most SLE patients are on hydroxychloroquine + immunosuppressant + corticosteroid + biologic + anticoagulant - any new agent risks drug-drug interactions); c-Met oncogenicity (SLE patients already carry an elevated background lymphoma risk, particularly diffuse large B-cell lymphoma; chronic c-Met activation is an additional concern); flare misattribution (any change in disease activity while taking an unproven peptide could be attributed to the peptide rather than to the underlying disease, delaying appropriate immunosuppressive escalation).

UK Resources, Charities & Specialist Services for Lupus

National charities: LUPUS UK (helpline 01708 731251, Romford); The Lupus Trust; Lupus Research Alliance (international); Versus Arthritis (broader rheumatology); Mind (NPSLE mood comorbidity); Samaritans 116 123.

NHS specialist services: GP referral to consultant rheumatology under BSR guideline; tertiary referral options include UCLH Centre for Rheumatology; Louise Coote Lupus Unit, Guy's and St Thomas'; Manchester / Salford Lupus Services; Bath / Royal United Hospital; the Birmingham SLE / NPSLE service; the Edinburgh, Glasgow, and Belfast tertiary services. NPSLE often requires joint rheumatology / neurology / psychiatry working.

Research & professional bodies: NIHR Be Part of Research for open SLE / NPSLE trials including CAR-T sites; British Society for Rheumatology (BSR); EULAR; American College of Rheumatology (ACR); Royal College of Psychiatrists (for NPSLE psychiatric presentations).

The 2026 Bottom Line

Lupus is the condition in this review series where the directionality risk for a synaptogenic peptide is most acute - and where the conventional treatment landscape is delivering the most consequential change in a generation. The Diamond / Volpe DNRAb paradigm makes NPSLE cognitive damage uniquely susceptible to amplification by an NMDA-augmenting intervention; memantine - an NMDA antagonist - reverses DNRAb damage in mice. The 2024 Erlangen CAR-T 11/12 drug-free remission cohort, the 2024 EU approval of the Saphnelo SC self-administration pen, the November 2025 BMS deucravacitinib PAISLEY 4-year safety/efficacy data with the now-enrolling POETYK SLE-1 / SLE-2 Phase 3 programme, the Biogen litifilimab anti-BDCA2 TOPAZ Phase 3 programme, the established belimumab pathway under NICE TA397 / TA752 and the voclosporin pathway for lupus nephritis under NICE TA882 collectively represent the most exciting therapeutic landscape lupus has ever seen - none of which involves any role for an unapproved synaptogenic peptide. No clinical trial of Dihexa in any lupus, SLE, cutaneous lupus, lupus nephritis or NPSLE population has been conducted, registered, or planned. The evidence-based 2026 UK pathway is GP-led prompt referral to consultant rheumatology under the BSR 2018 guideline, with hydroxychloroquine cornerstone, conventional DMARDs, NICE-recommended biologics where eligible, tertiary NPSLE specialist referral for cognitive / psychiatric presentations, and LUPUS UK and the Lupus Trust for patient navigation. The DNRAb paradigm is a uniquely strong argument against any synaptic-plasticity-augmenting peptide in NPSLE cognitive dysfunction - not for it.

Selected References & External Sources

1. Yen EY, Singh DR, Singh RR (2024). UK SLE incidence and prevalence 1990-2020 (CPRD). — PMC11284910
2. Gordon C et al. (2018). BSR guideline for the management of SLE in adults. Rheumatology. — Oxford
3. BSR 2024 SLE guideline scope (children, young people and adults). Rheumatology Advances in Practice. — PMC10695902
4. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B (2001). Anti-dsDNA/NR2 cross-reactive antibodies in SLE. Nat Med. — Nature Medicine
5. Faust TW, Chang EH, Kowal C, Berlin R, Volpe BT, Diamond B et al. (2010). Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. PNAS. — PNAS
6. Diamond B et al. PMC NMDAR autoantibody review. — PMC1702320 · PMC1755620
7. Watson RR, Reichlin M et al. (1983). Lupus brain-reactive antibodies. PNAS. — PNAS
8. Bonfa E et al. (1987). Lupus psychosis and anti-ribosomal P protein antibodies. NEJM. — NEJM
9. CSF intrathecal synthesis of anti-NR2 in NPSLE. — PMC4060173
10. Hanly et al. Cognitive dysfunction in SLE; NPSLE pooled prevalence. — PMC4302271 · Lupus Sci Med
11. S100A8/A9 and MMP-9 in SLE cognitive impairment (2024). — PMC10851148
12. Mougiakakos D, Mackensen A, Schett G et al. (2021). CD19 CAR-T in refractory SLE. NEJM. — NEJM
13. Mackensen A et al. (2022). Anti-CD19 CAR-T therapy for refractory SLE. Nat Med. — Nature Medicine
14. CAR-T autoimmune disease NEJM 2022. — NEJM PDF
15. Erlangen CAR-T SLE QoL preliminary (2025). J Rheumatol. — J Rheumatol PDF
16. CAR-T SLE current status and future perspectives (2024 Frontiers). — Frontiers Immunology
17. NICE TA397 belimumab SLE (June 2016). — nice.org.uk/guidance/ta397
18. NICE TA752 belimumab subcutaneous SLE (2021). — nice.org.uk/guidance/ta752
19. NICE TA793 anifrolumab terminated appraisal. — nice.org.uk/guidance/ta793
20. NICE TA882 voclosporin lupus nephritis (April 2023). — nice.org.uk/guidance/ta882
21. Saphnelo (anifrolumab) SC pen EU CHMP recommendation (September 2024). — AstraZeneca CHMP
22. Saphnelo SC pen EU approval (Q4 2024). — AstraZeneca EU
23. Update on Saphnelo subcutaneous US regulatory (2026). — AstraZeneca 2026
24. Anifrolumab TULIP-1 / TULIP-2 evidence base PMC. — PMC11299632
25. BMS Sotyktu (deucravacitinib) ACR Convergence November 2025 late-breaking SLE. — BMS press release
26. PAISLEY-SLE 4-year safety and efficacy ACR abstracts. — ACR abstracts
27. POETYK SLE-1 and POETYK SLE-2 Phase 3 design. — PubMed 40920289
28. Litifilimab (BIIB059) Phase 2 CLE NEJM. — NEJM
29. Biogen litifilimab Phase 3 SLE first patient dosed. — Biogen
30. Biogen multiple assets and indications in lupus. — Biogen
31. EG-501 NPSLE Phase 2 trial. — NCT07281105
32. LUPUS Brain tACS NPSLE trial. — NCT04141046
33. BDNF in SLE: Petri 2021 cohort of 111. — Clinical Rheumatology
34. Eilat 2013 serum & lymphocytic neurotrophin SLE case-control. — PubMed 24223945
35. HSS Neuropsychiatric Lupus and the Brain. — HSS
36. Cognitive assessment in SLE (Creyos). — Creyos
37. European diagnostic delay analysis (2022 medRxiv). — medRxiv
38. LUPUS UK. — lupusuk.org.uk · The Lupus Trust. — lupustrust.uk · Lupus Research Alliance. — lupusresearch.org
39. British Society for Rheumatology. — rheumatology.org.uk · EULAR. — eular.org · ACR. — rheumatology.org
40. NIHR Be Part of Research. — bepartofresearch.nihr.ac.uk
41. Benoist et al. (2014). HGF/c-Met dependence of Dihexa procognitive / synaptogenic effects. JPET. — PubMed 24403718
42. Wright & Harding (2015). Brain HGF/c-Met system. — PubMed 25711386